jte 522 has been researched along with docetaxel anhydrous in 1 studies
| Studies (jte 522) | Trials (jte 522) | Recent Studies (post-2010) (jte 522) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
|---|---|---|---|---|---|
| 61 | 1 | 7 | 12,110 | 3,216 | 6,920 |
| Protein | Taxonomy | jte 522 (IC50) | docetaxel anhydrous (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hida, T; Ito, H; Kozaki, K; Matsuo, K; Miyaishi, O; Ogawa, M; Sugiura, T; Suzuki, T; Takahashi, T; Tatematsu, Y | 1 |
1 other study(ies) available for jte 522 and docetaxel anhydrous
| Article | Year |
|---|---|
Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.
Topics: Adenocarcinoma; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Isoenzymes; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Transplantation; Oxazoles; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |